Wir sind mit live! Mehr erfahren

Fortrea Holdings

FTRE

Börsenwert 2,14 Mrd. $

22,49 USD

-0,26

1,14 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

22,93

+0,44

1,96 %

1 Tag

-1,14 %

5 Tage

7,92 %

1 Monat

12,62 %

3 Monate

25,5 %

6 Monate

122,89 %

Seit Jahresbeginn

33,79 %

1 Jahr

136,24 %

5 Jahre

-25,28 %

10 Jahre

-25,28 %

Profil: Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.

Mitarbeiter: 14.000

Gesundheitswesen Biotechnologie

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 52,9 %

Neutral 47,1 %

Negativ 0 %

3 Top Small-Cap Stocks With Market-Beating Momentum

Small-cap stocks have surrendered their lead over large caps in 2026 amid rising Treasury yields, but historical data shows small caps can rebound strongly when yields decline. Bank of America strategists see potential for a small-cap rebound if the 10-year Treasury yield peaks around their year-end forecast of 5%. I highlight three fundamentally strong small-cap stocks that have outperformed the market since the Russell 2000's recent high, defying the index's broader weakness.

3 Top Small-Cap Stocks With Market-Beating Momentum

Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call

DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third quarter 2026 financial results before the market opens on Thursday, October 29, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results.

Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call

Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of restricted stock units (“RSUs”) and performance share units (“PSUs”) on September 10, 2026, to five newly hired employees.

Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fortrea to Participate in September Investor Conferences

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations, Tracy Krumme will participate in the following conferences in September:

Fortrea to Participate in September Investor Conferences

Fortrea Leverages Early Phase Strengths to Accelerate Market Expansion

Fortrea (NASDAQ:FTRE) signed a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials in an all-cash transaction valued at approximately $45 million.

Fortrea Leverages Early Phase Strengths to Accelerate Market Expansion

Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials

Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets

Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials

Fortrea Holdings: The Turnaround Is Showing Up In Earnings Before Revenue

Fortrea Holdings Inc. is rated Buy at ~$18.86, driven by an earnings turnaround from aggressive cost reductions, not revenue growth. Adjusted EBITDA rose ~24% in H1 despite a ~3.4% revenue decline, as direct costs and SG&A fell faster than sales. Net new business awards increased ~19% YoY, with a trailing-12-month book-to-bill ratio of 1.12x, but revenue conversion remains uncertain.

Fortrea Holdings: The Turnaround Is Showing Up In Earnings Before Revenue

Zacks Investment Research

Fortrea Holdings Inc. (FTRE) Upgraded to Strong Buy: Here's What You Should Know

Fortrea Holdings Inc. (FTRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Fortrea Holdings Inc. (FTRE) Upgraded to Strong Buy: Here's What You Should Know

Zacks Investment Research

FTRE vs. ARGX: Which Stock Is the Better Value Option?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

FTRE vs. ARGX: Which Stock Is the Better Value Option?

Zacks Investment Research

Best Momentum Stock to Buy for July 31st

FTRE, ASML and KLAC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 31, 2026.

Best Momentum Stock to Buy for July 31st

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt